-
Testing services growth of 23% was driven by a layering effect of kidney centers restarting surveillance protocols and expanded for-cause utilization.
-
The solution selling strategy successfully integrated digital and pharmacy offerings, resulting in 47% year-over-year growth for Patient and Digital Solutions.
-
Revenue Cycle Management (RCM) transitioned from stabilization to a core strength, reducing claim rejection rates by over 60% through automation and AI deployment.
-
The Lab Products segment benefited from a global market transition toward NGS-based HLA typing, where the company maintains a leadership position.
-
Strategic infrastructure investments, specifically the Epic Aura integration, are designed to reduce clinical friction and improve electronic order data quality.
-
Clinical evidence generation remains the foundation for adoption, highlighted by SHORE registry data demonstrating HeartCare’s prognostic value beyond traditional biopsy.
-
Management emphasized a disciplined capital allocation strategy, returning capital via share repurchases while maintaining a debt-free balance sheet with $200,000,000 in cash.
-
Full year 2026 revenue guidance of $420,000,000 to $444,000,000 assumes a $7,500,000 headwind from the anticipated midyear finalization of the Medicare LCD.
-
The ‘Transplant Plus’ strategy focuses on the 2026 CLIA readiness of Allaheme, targeting commercial introduction into the cell therapy market by early 2027.
-
Operational guidance includes a $10,000,000 investment in enterprise systems, including an 18-month migration to Epic Enterprise LIMS to streamline multi-site data exchange.
-
Volume guidance of 12% growth at the midpoint is characterized as conservative, excluding potential procedural volume increases or immediate lift from new Epic integrations.
-
Management targets a long-term 20% adjusted EBITDA margin, supported by a 50% flow-through of incremental gross profit dollars to the bottom line.
-
A pricing reset for AlloSure Kidney went into effect on 01/01/2026, reducing reimbursement by 4% from $2,841 to $2,753 via a new PLA code.
-
The company implemented a one-time $6,700,000 cash bonus for nonexecutives in lieu of equity to manage shareholder dilution and normalize the employee burn rate.
-
Management transition announced with Keith Kennedy assuming the dual role of COO and CFO following the departure of Nathan Smith.
-
The anticipated Medicare LCD remains a primary variable, with guidance modeling a scenario where only one test per date of service is reimbursed for heart transplants.
